Athenex is a biopharmaceutical company focused on the discovery, development and commercialization of products for the treatment of cancer. Co. manages its operations in two reportable segments: Oncology Innovation Platform, which is focused on the research and development of its proprietary drugs and; Commercial Platform, which focused on the sales and marketing of drugs and the market development of its proprietary drugs. Co. is also continuing certain studies of oral paclitaxel and encequidar, the active product candidate using its Orascovery technology, based on a P-glycoprotein pump inhibitor.
|
Free ATNX Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Hold (2.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Analysts' Target Price: ATNX Stock Forecast Based on Zacks ABR data; powered by Xignite |